Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 6/2013

01.12.2013 | Gynecologic Cancers (NS Reed, Section Editor)

A Review of Treatment of Uterine Leiomyosarcomas

verfasst von: Nicholas Reed

Erschienen in: Current Oncology Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Uterine leiomyosarcomas are rare but challenging tumours. They occur most commonly around or shortly after the menopause. Their clinical behaviour is very variable, from highly aggressive to very indolent. Most are diagnosed unexpectedly and thus initially operated on by general gynaecologists. This article discusses the important surgical issues and the role of adjuvant treatments such as radiotherapy and chemotherapy. Important new international trials are opening to address these issues. Relapsed disease is usually incurable, but a subgroup of patients may benefit from repeated surgical procedures, hormones and ablative therapies. The choice of drugs for chemotherapy is discussed. New approaches with targeted agents have yet to establish themselves in treatment of leiomyosarcomas.
Literatur
1.
Dinh TA, Woodruff JD. Leiomyosarcoma of the uterus. Am J Obstet Gynecol. 1982;144:817–23.PubMed
2.
Schwartz LB, Diamond MP, Schwartz MP. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol. 1993;168:180–3.PubMedCrossRef
3.
Brooks SE, Zhan M, Baquet C. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93:204–8.PubMedCrossRef
4.
Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases with emphasis on diagnostic criteria and prognostic factors. Cancer. 1988;62:2239–47.PubMedCrossRef
5.
Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms: a clinicopathological study of 213 cases. Am J Surg Pathol. 1994;18:535–58.PubMedCrossRef
6.
Hendrickson M, Longacre T, Kempson R. Pathology of uterine sarcomas. In: Coukos G, Rubin SC, editors. Cancers of uterus. New York: Dekker; 2005. p. 149–95.
7.
• Mehine M, Kaasinen E, Makinen N, Katainen R, Kampjarvi K, Pitkanen E, et al. Characterisation of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013. doi:10.​1056/​NEJMoal1302736. Interesting article helping to evaluate potential new targets.
8.
• Farid M, Ong WS, Tan MH, et al. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extra-uterine disease. Am J Clin Oncol. 2013;36:368–74. Useful article on differences between uterine and extra-uterine tumours.
9.
Leibsohn S, d’Ablaing G, Misell DR, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162:968–74.PubMedCrossRef
10.
Shah SH, Jagannathan JP, Krajewski K, O’Regan KN, George S, Ramaiya NH. Uterine sarcomas: then and now. AJR Am J Roentgenol. 2012;199:213–23.PubMedCrossRef
11.
Amant F. The rationale for comprehensive surgical staging in endometrial carcinosarcoma. Gynecol Oncol. 2005;99(2):521–2.PubMedCrossRef
12.
Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702–9.PubMedCrossRef
13.
Goff BA, Rice LW, Fleischhacker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993;50:105–9.PubMedCrossRef
14.
Oláh KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol. 1992;99(7):590–4.PubMedCrossRef
15.
Dinh TA, Oliva EA, Fuller AF, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10 year experience (1990–1999) at Massachusetts General Hospital. Gynecol Oncol. 2004;92:648–52.PubMedCrossRef
16.
Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;62:25–32.PubMedCrossRef
17.
Giuntoli RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460–9.PubMedCrossRef
18.
Yoshida Y, Kurokawa K, Sawamura Y, et al. Comparison of 18FDG PET and MRI in Assesment of Uterine Smooth Muscle Tumours. J Nuclear Med. 2008;49:708-12.
19.
Prayson RA, Goldblum JR, Hart WR. Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients. Am J Surg Pathol. 1997;21(4):383–91.PubMedCrossRef
20.
Reichardt P. The treatment of uterine sarcomas. Ann Oncol. 2012;23 Suppl 10:151–7.CrossRef
21.
Tierney JF, Mosseri V, Stewart LA, Souhami R, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer. 1995;72(2):469–75.PubMedCrossRef
22.
Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma. Is there a standard of care? J Clin Oncol. 2001;19:1235–7.PubMed
23.
Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–47.PubMed
24.
Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3(9):1240–5.PubMed
25.
Muss H, Omura GA, Blessing JA, Major FJ, Lifshitz S, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1240–5.
26.
Buchsbaum HJ, Lifshitz S, Blythe JG. Prophylactic chemotherapy in stages I and II uterine sarcoma. Gynecol Oncol. 1979;8:346–8.PubMedCrossRef
27.
Hannigan EV, Freedman RS, Rutledge FN. Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol. 1983;15:56–64.PubMedCrossRef
28.
van Nagell JR, Hanson Jr MB, Donaldson ES, et al. Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer. 1986;57(8):1451–4.PubMedCrossRef
29.
Piver MS, Lele SB, Marchetti DL, et al. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol. 1988;38(4):233–9.PubMedCrossRef
30.
Hempling RE, Piver MS, Baker TR. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. Am J Clin Oncol. 1995;18:282–6.PubMedCrossRef
31.
Gadducci A, Romanini A. Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol. 2001;22(5):352–7.PubMed
32.
Odunsi K, Moneke V, Tammela J, et al. Efficacy of adjuvant CYVADIC chemotherapy in early stage uterine sarcomas: results of long-term follow-up. Int J Gynecol Cancer. 2004;14:659–64.PubMedCrossRef
33.
Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol. 2006;100:166–72.PubMedCrossRef
34.
•• Gupta AA, Yao X, Verma S, Mackay H, Hopkins L. Sarcoma Disease Site Group, Gynecology Cancer Disease Site Group. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review. Clin Oncol. 2013;25:346–55. Recent meta-analysis on treatment of relapsed disease.
35.
Martin-Liberal J, Benson C. Systemic chemotherapy for inoperable, locally advanced, recurrent or metastatic uterine leiomyosarcoma. Clin Oncol. 2013;25:343–5.CrossRef
36.
Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma. Results of a prospective study. Gynecol Oncol. 2009;112(3):563–7.PubMedCrossRef
37.
• Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119(8):1555–61. Recent approaches to improving care.
38.
Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013;24(4):1099–104.PubMedCrossRef
39.
Edwards CL. Undifferentiated tumours. In: Cancer of the uterus and ovary. Chicago: Year Book; 1969. p. 84–94
40.
Badib AO, Vongtama V, Kurohara SS, Webster JH. Radiotherapy in the treatment of sarcomas of the corpus uteri. Cancer. 1969;24:724–9.PubMedCrossRef
41.
Belgrad R, Elbadawi N, Rubin P. Uterine sarcoma. Radiology. 1975;144(1):181–8.
42.
Salazar O, Bonfiglio TK, Patten SF, Kellser BE, Feldstein ME, Dunne ME, et al. Uterine sarcomas: natural history, treatment and prognosis. Cancer. 1978;42:1152–60.PubMedCrossRef
43.
Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein ML, Dunne ME, et al. Uterine sarcomas. Analysis of failures with special emphasis on the use of adjuvant radiotherapy. Cancer. 1978;42:1161–70.PubMedCrossRef
44.
Sorbe B. Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol. 1985;20:281–9.PubMedCrossRef
45.
Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 1986;12(12):2127–30.PubMedCrossRef
46.
Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol. 2001;27(3):282–5.PubMedCrossRef
47.
Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997;65:493–8.PubMedCrossRef
48.
Dusenbery KE, Potish RA, Agenta PA, et al. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol. 2005;28:295–300.PubMedCrossRef
49.
Mahdavi A, Monk BJ, Ragazzo J, Hunter MI, Lentz SE, Vasilev SA, et al. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. Int J Gynecol Cancer. 2009;19(6):1080–4.PubMedCrossRef
50.
Reed NS, Mangioni C, Malmstrom H, et al. First results of a randomised trial comparing radiotherapy versus- observation post operatively in patients with uterine sarcomas, an EORTC-GCG study. Eur J Cancer. 2008;44(6):808–18.PubMedCrossRef
51.
Kanjeekal S, Chambers A, Kee Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol. 2005;97:624–37.PubMedCrossRef
52.
Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al. A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–32.PubMedCrossRef
53.
Hannigan EV, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with vincristine, actinomycin D and cyclophosphamide. Gynecol Oncol. 1983;15:224–9.PubMedCrossRef
54.
Sutton GP, Blessing JA, Rosenshein N, Photopoulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1989;161:309–15.PubMedCrossRef
55.
Thigpen T, Blessing JA, Wilbanks GD. Cisplatin as second line therapy in the treatment of patients with advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the gynecologic oncology group. Am J Clin Oncol. 1986;9:18–20.PubMedCrossRef
56.
Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1991;9:1962–6.PubMed
57.
Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992;166:556–9.PubMedCrossRef
58.
Sutton GP, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62:226–9.PubMedCrossRef
59.
Leyvraz S, Bacchi M, Lissoni A, Sessa C, Cerny T, Honegger HP. High response rate with the combination of high-dose ifosfamide and doxorubicin for the treatment of advanced gynecologic sarcomas. Proc Am Soc Clin Oncol. 1998;17:354a.
60.
Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;74:346–9.PubMedCrossRef
61.
Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Phase II trial of topotecan in patients with advanced, persistent or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study. Am J Clin Oncol. 2000;23:355–7.PubMedCrossRef
62.
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;12:2824–31.CrossRef
63.
Gallup DG, Blessing JA, Andersen W, Morgan MA. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2003;89:48–51.PubMedCrossRef
64.
Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–50.PubMedCrossRef
65.
Look KY, Sandler A, Blessing JA, Lucci III JA, Rose PG. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a gynecologic oncology group (GOG) study. Gynecol Oncol. 2004;92:644–7.PubMedCrossRef
66.
Leyvraz S, Zweifel M, Jundt G, Lissoni A, Cerny T, Sessa C, et al. Long-term results of a multicenter SAKK trial on highdose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol. 2006;17:646–51.PubMedCrossRef
67.
Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2002;507–10.
68.
Hensley ML, Blessing J, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109:329–34.PubMedCrossRef
69.
Schoffski P, Wolter P, Clement P, Sciot R, De Wever I, Wozniak A, et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol. 2007;3(4):381–92.PubMedCrossRef
70.
Amant F, Coosemans A, Renard V, Everaert E, Vergote I. Clinical outcome of ET-743 (trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int J Gynecol Cancer. 2009;19(2):245–8.PubMedCrossRef
71.
Sanfilippo R, Grosso F, Jones RL, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011;123(3):553–6.PubMedCrossRef
72.
Ray-Coquard I. An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas. Int J Gynecol Cancer. 2011;21 Suppl 1:S3–5.PubMedCrossRef
73.
Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;124(1):48–52.PubMedCrossRef
74.
Garber K. IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst. 2005;97(11):790–2.PubMedCrossRef
75.
Vu TH, Yballe C, Boonyanit S, Hoffman AR. Insulin-like growth factor II in uterine smooth-muscle tumors: maintenance of genomic imprinting in leiomyomata and loss of imprinting in leiomyosarcomata. J Clin Endocrinol Metab. 1995;80(5):1670–6.PubMedCrossRef
76.
Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol. 2009;217(4):469–82.PubMedCrossRef
77.
King ER, Wong KK. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov. 2012;7(1):14–30.PubMedCrossRef
78.
Hernando H, Charytonowicz E, Dudas ME, Menendez S, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13:748–53.PubMedCrossRef
79.
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.PubMedCrossRef
80.
O’Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116:424–9.PubMedCrossRef
81.
Levenback C, Rubin SC, McCormack PM, et al. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol. 1992;45:202–5.PubMedCrossRef
82.
Leitao MM, Brennan MF, Hensley M, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002;87:287–94.PubMedCrossRef
83.
Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary metastasis: a 20-year experience. Ann Thorac Surg. 1984;38:323–30.PubMedCrossRef
84.
Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol. 2008;18(4):672–7.PubMedCrossRef
85.
Giuntoli II RL, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106(1):82.PubMedCrossRef
86.
• Zivanovic O, Jacks LM, Iasonos A, Leitao Jr MM, Soslow RA, Veras E, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2012;118(3):660–9. doi:10.​1002/​cncr.​26333. Use of a predictive nomogram to improve care.
Metadaten
Titel
A Review of Treatment of Uterine Leiomyosarcomas
verfasst von
Nicholas Reed
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 6/2013
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-013-0350-4

Weitere Artikel der Ausgabe 6/2013

Current Oncology Reports 6/2013 Zur Ausgabe

Cancer Prevention (J Cuzick, Section Editor)

Helicobacter pylori Eradication in the Prevention of Gastric Cancer: Are More Trials Needed?

Invited Commentary

Latest Developments in the Biology and Management of Uveal Melanoma

Cancer Prevention (J Cuzick, Section Editor)

Role of Aspirin in Cancer Prevention

Cancer Prevention (J Cuzick, Section Editor)

Sun Exposure, Sunbeds and Sunscreens and Melanoma. What Are the Controversies?

Gynecologic Cancers (NS Reed, Section Editor)

“Unresectable” Vulval Cancers: Is Neoadjuvant Chemotherapy the Way Forward?

Gynecologic Cancers (NS Reed, Section Editor)

Functional Imaging to Predict Tumor Response in Locally Advanced Cervical Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise